- Home
- USCB vs ABEO Comparison
USCB vs ABEO Comparison
Compare USCB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USCB | ABEO |
|---|---|---|
| Founded | 2002 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.1M | 280.2M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | USCB | ABEO |
|---|---|---|
| Price | $18.51 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $22.00 | $18.75 |
| AVG Volume (30 Days) | 34.2K | ★ 1.3M |
| Earning Date | 04-23-2026 | 03-17-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 7.26 | ★ 165.16 |
| EPS | ★ 1.33 | 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $26.46 | $1,276.65 |
| Revenue Next Year | $9.67 | $112.53 |
| P/E Ratio | $13.42 | ★ $4.41 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $15.39 | $3.93 |
| 52 Week High | $20.79 | $7.54 |
Technical Indicators
Market Signals| Indicator | USCB | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 33.09 |
| Support Level | $17.80 | $4.00 |
| Resistance Level | $18.69 | $5.52 |
| Average True Range (ATR) | 0.55 | 0.23 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 47.96 | 11.44 |
Price Performance
Historical ComparisonAbout USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.